StockData
Obsidian Therapeutics, Inc. logo

Obsidian Therapeutics, Inc. (OBX) stock

OBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$12.00−0.15 (-1.23%)

Close on Nov 20, 2026Market cap $741.28MP/E –Yield –

Obsidian Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$27.55M–
Q3 FY2025Sep 30, 2025$25.05M–

More Obsidian Therapeutics figures

See a number that looks wrong?